Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Pulmonology

What Do Ground-Glass Opacities and NSIP Mean on an ASyS CT?

At a Glance

On an antisynthetase syndrome CT scan, ground-glass opacities and NSIP are imaging patterns that can reflect lung inflammation, scarring, or another cause. Doctors combine the scan with symptoms, oxygen levels, and lung function tests to decide what they mean and how to monitor or treat them.

Reading a High-Resolution Computed Tomography (HRCT) report can be incredibly stressful, especially when it is full of terms you have never seen before. If your report mentions ground-glass opacities and NSIP, it means your scan is showing specific radiologic patterns [1]. In someone with Antisynthetase Syndrome (ASyS), these findings may reflect active inflammation in the lungs [2]. However, a CT scan is just one piece of the puzzle; your doctor will look at your symptoms and pulmonary function tests (PFTs) to understand what these patterns mean for your specific situation [3].

When to Seek Urgent Care
A new or rapidly worsening ground-glass opacity can sometimes represent an infection, fluid build-up, or another urgent issue rather than an ASyS flare. Seek immediate medical attention for rapidly increasing shortness of breath, sudden low oxygen readings, blue lips, severe chest pain, coughing up blood, confusion, or a high fever.

CT Findings Are Patterns, Not Diagnoses

It is important to know that terms like “ground-glass opacity” and “NSIP” describe how abnormalities look on a scan; they are not diagnoses themselves. While they are very common in ASyS-associated interstitial lung disease, they can also occur with other autoimmune diseases, infections, or medication reactions [1].

Decoding the Jargon: Ground-Glass Opacities

Ground-glass opacities (GGOs) get their name from how they look on a scan. Imagine looking through a piece of frosted glass—it is hazy, but you can still see objects behind it. On a CT scan, ground-glass opacities are gray, hazy patches where the lung tissue is not completely solid but less clear than normal air-filled lung [4].

While GGOs are a nonspecific finding that can be caused by fluid, infection, or scarring, in someone with known ASyS they often suggest an active inflammatory component [4]. When these hazy areas represent inflammation, they are potentially reversible with treatment [5]. In patients whose lung disease improves, the extent of ground-glass opacities often physically decreases on follow-up scans [5]. However, a CT scan cannot definitively prove whether a ground-glass area is active inflammation or early scarring just by looking at it [6].

Decoding the Jargon: NSIP and OP

Radiologists use acronyms to describe the overall “pattern” or distribution of the abnormalities. In ASyS, these patterns often appear in the lower parts and outer edges of the lungs [1].

  • NSIP (Nonspecific Interstitial Pneumonia): Despite the confusing name, “nonspecific” just means the pattern did not fit into older categories of lung disease when it was first named. Today, it is recognized as one of the most classic patterns of lung involvement in ASyS [2]. Under a microscope, NSIP can be predominantly “cellular” (mostly inflammatory) or “fibrotic” (involving scar tissue) [7]. A CT scan can suggest which type is more likely, but the distinction may be uncertain without looking at the broader clinical context.
  • OP (Organizing Pneumonia): This is another common pattern often seen alongside NSIP, sometimes called an “NSIP-OP overlap” [2]. It describes areas where organizing inflammatory material has gathered in the small airways and distal airspaces [7]. Like cellular NSIP, OP patterns driven by autoimmune disease can be highly responsive to treatment, but they can also have other causes.

What This Scan Can and Cannot Tell You

When your pulmonologist reads your CT scan, they are trying to estimate how much of the lung involvement is potentially reversible inflammation versus established fibrosis (scarring).

  • Signs that may suggest inflammation: Ground-glass opacities, consolidation (denser white areas), and OP patterns [4]. These suggest that the disease may be active and potentially treatable with immunosuppressive medications [8].
  • Signs that may suggest scarring (fibrosis): If your report mentions terms like reticulation (a net-like pattern, which can sometimes just be thickening but often suggests scarring), traction bronchiectasis (stretched-out airways), or honeycombing (clusters of cysts), these indicate established fibrotic remodeling [4][1]. Fibrotic patterns tend to persist, so treatment focuses on protecting the remaining healthy lung tissue and stopping the scarring from worsening [7].

Treatment and Monitoring

You should never start, stop, or change treatments based on a CT report alone. Your doctor will combine these findings with your symptoms, oxygen levels, and Pulmonary Function Test (PFT) trends—specifically values like FVC (Forced Vital Capacity) and DLCO (diffusing capacity)—to determine your next steps [3][9].

If treatment is needed for active ASyS lung involvement, medications like corticosteroids or steroid-sparing agents (such as mycophenolate, azathioprine, or rituximab) might be discussed [10][11]. The choice of medication depends on disease severity, your overall health, and infection risks, as all immunosuppressants require careful monitoring.

While many patients experience stabilization or improvement in lung function and scan appearances over time [5][12], the degree and speed of recovery vary [7]. Because ASyS can sometimes flare up again later, your care team will tailor a long-term monitoring plan that includes regular PFTs and occasional follow-up CT scans [3][13].

Common questions in this guide

What do ground-glass opacities mean on an antisynthetase syndrome CT scan?
Ground-glass opacities are hazy areas on a CT scan where the lung looks less clear than normal but is not completely solid. In antisynthetase syndrome, they may reflect active inflammation and can improve with treatment, but they can also result from infection, fluid, medication effects, or early scarring.
What does NSIP mean in antisynthetase syndrome?
NSIP stands for nonspecific interstitial pneumonia and describes a pattern of lung involvement, not a diagnosis by itself. In antisynthetase syndrome, it may be mostly inflammatory, called cellular NSIP, or include more established scar tissue, called fibrotic NSIP, and a CT scan may not distinguish these with certainty.
Does ground glass on a CT prove that my lung inflammation is active?
No. A CT scan alone cannot reliably tell whether every ground-glass area is active inflammation, early scarring, infection, or another problem. Doctors interpret the scan with your symptoms, oxygen levels, and lung function tests such as FVC and DLCO.
What is an NSIP-OP overlap pattern?
An NSIP-OP overlap means the scan has features of nonspecific interstitial pneumonia and organizing pneumonia. In autoimmune lung disease, organizing pneumonia and the inflammatory part of NSIP can respond well to treatment, although other causes are possible.
Which CT findings suggest lung scarring or fibrosis?
Reticulation, traction bronchiectasis, and honeycombing can suggest established fibrotic remodeling, or scarring, in the lungs. These findings often persist, so care focuses on protecting remaining lung function and limiting further progression.
When should I seek urgent care for changes on my CT or breathing?
Seek immediate medical attention for rapidly worsening shortness of breath, a sudden low oxygen reading, blue lips, severe chest pain, coughing up blood, confusion, or a high fever. A new or rapidly increasing ground-glass opacity can have urgent causes such as infection or fluid buildup and should not automatically be assumed to be an antisynthetase syndrome flare.
How are CT findings used to decide treatment for ASyS lung disease?
Your doctor combines the CT pattern with symptoms, oxygen levels, and changes in FVC and DLCO rather than treating the scan alone. If active lung inflammation is suspected, corticosteroids or steroid-sparing medicines such as mycophenolate, azathioprine, or rituximab may be discussed, with monitoring for infection and other risks.

Get notified when new evidence is published on Antisynthetase syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    Antisynthetase syndrome: Pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases.

    Waseda Y, Johkoh T, Egashira R, et al.

    European journal of radiology 2016; (85(8)):1421-6.

    PMID: 27423682
  2. 2

    [Clinical characteristics of patients with antisynthetase syndrome and interstitial pulmonary disease].

    Li W, Li J, Xie WM, et al.

    Zhonghua yi xue za zhi 2020; (100(24)):1861-1865 doi:10.3760/cma.j.cn112137-20191120-02521.

    PMID: 32575928
  3. 3

    Predictive Factors for the Long-Term Deterioration of Pulmonary Function in Interstitial Lung Disease Associated with Anti-Aminoacyl-tRNA Synthetase Antibodies.

    Yamakawa H, Hagiwara E, Kitamura H, et al.

    Respiration; international review of thoracic diseases 2018; (96(3)):210-221 doi:10.1159/000488358.

    PMID: 29768275
  4. 4

    Computed Tomography Findings as Determinants of Local and Systemic Inflammation Biomarkers in Interstitial Lung Diseases: A Retrospective Registry-Based Descriptive Study.

    Lang D, Akbari K, Horner A, et al.

    Lung 2021; (199(2)):155-164 doi:10.1007/s00408-021-00434-w.

    PMID: 33770227
  5. 5

    Evolution of Pulmonary Function in a Cohort of Patients with Interstitial Lung Disease and Positive for Antisynthetase Antibodies.

    González-Pérez MI, Mejía-Hurtado JG, Pérez-Román DI, et al.

    The Journal of rheumatology 2020; (47(3)):415-423 doi:10.3899/jrheum.181141.

    PMID: 31203227
  6. 6

    Interstitial lung disease associated with anti-aminoacyl-tRNA synthetase syndrome: quantitative evaluation of CT after initial treatment and long-term follow-up.

    Aoki R, Iwasawa T, Utsunomiya D, et al.

    Acta radiologica (Stockholm, Sweden : 1987) 2024; (65(11)):1332-1340 doi:10.1177/02841851241281492.

    PMID: 39530602
  7. 7

    Antisynthetase syndrome-related interstitial lung disease (ASyS-ILD): longitudinal imaging findings.

    Wu W, Collins BF, Gardner GC, et al.

    European radiology 2023; (33(7)):4746-4757 doi:10.1007/s00330-023-09439-w.

    PMID: 36786906
  8. 8

    [Anti-synthetase syndrome treatment].

    Martellosio JP, Martin M, Broca F, et al.

    La Revue de medecine interne 2026; doi:10.1016/j.revmed.2026.07.008.

    PMID: 42562676
  9. 9

    Relationship between high-resolution computed tomography quantitative imaging analysis and physiological and clinical features in antisynthetase syndrome-related interstitial lung disease.

    Bae SS, Abtin F, Kim G, et al.

    RMD open 2024; (10(4)) doi:10.1136/rmdopen-2024-004592.

    PMID: 39608864
  10. 10

    [Clinical and radiological features of adult patients with different antisynthetase syndrome based on serum anti-aminoacyl-tRNA synthetase antibody type].

    Li S, Huang H, Song XY, et al.

    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 2017; (40(12)):919-924 doi:10.3760/cma.j.issn.1001-0939.2017.12.011.

    PMID: 29224302
  11. 11

    Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review.

    Doyle TJ, Dhillon N, Madan R, et al.

    The Journal of rheumatology 2018; (45(6)):841-850 doi:10.3899/jrheum.170541.

    PMID: 29606668
  12. 12

    Longitudinal Trajectories of Antisynthetase Syndrome-associated Interstitial Lung Disease.

    Billotte M, Camara H, Meyer A, et al.

    Archivos de bronconeumologia 2026; doi:10.1016/j.arbres.2026.05.015.

    PMID: 42309931
  13. 13

    An observational study of clinical recurrence in patients with interstitial lung disease related to the antisynthetase syndrome.

    Chen H, Liu H, Lyu W, et al.

    Clinical rheumatology 2023; (42(3)):711-720 doi:10.1007/s10067-022-06424-4.

    PMID: 36334174

This page is for informational purposes only and does not constitute medical advice. Your pulmonologist and care team should interpret your CT, lung function tests, symptoms, and oxygen levels before making treatment decisions.